Cuts Are Coming for Glaxo R&D

February 4th, 2010 admin

GlaxoSmithKline is going to cut R&D and other expenses as part of an effort to lower costs. The company wouldn’t specify how many jobs will be lost. But CEO Andrew Witty said that the figure in the U.K., where Glaxo is based, would likely be in the hundreds, Dow Jones Newswires reports . The Times of London and the Financial Times reported a few days back that GSK was planning to cut 3,000 to 4,000 jobs. In its fourth-quarter earnings release today, the company said it is proposing the “cessation of discovery research in selected areas including depression and pain,” and looking to establish a new unit for research into rare diseases. The company says it plans to save an…


Originally posted on WSJ

 
  Related Posts
Pfizer Plans to Cut Billions in Annual R&D Spending
Pfizer Plans to Cut Billions in Annual R&D Spending
Pfizer spent $2.8 billion on R&D in the fourth quarter of last year, according to today’s earnings announcement from the company. But R&D spending is about to fall pretty sharply, according to estimates from the company. This is no surprise — the big spending in the fourth quarter was largely the result of the company’s... 
Genzyme Puts Numbers on Its Woes; Icahn Raises His Stake
Genzyme Puts Numbers on Its Woes; Icahn Raises His Stake
Manufacturing setbacks put a big dent in Genzyme’s fourth-quarter profit and the company’s outlook for 2010 earnings was lower than analysts had expected. If that wasn’t enough to worry about, Carl Iachn has upped his stake in the biotech. Well-chronicled problems with viral contamination shut down a Massachusetts manufacturing... 
Boston Scientific Cuts Jobs; Defibrillator Safety Questioned
Boston Scientific Cuts Jobs; Defibrillator Safety Questioned
A few Boston Scientific-related news bites: The company said it will cut 1,000 to 1,300 jobs over the next few years, as part of a restructuring program. That’s out of a work force of about 25,000. The company also reported earnings and gave new guidance; those figures are unpacked in this Dow Jones Newswires story . Two brands of Boston... 
Lilly’s Effient: Slow Start for a New Blood Thinner
Lilly’s Effient: Slow Start for a New Blood Thinner
Eli Lilly executives said there’s every reason to be optimistic about future sales of Effient, the blood thinner launched last summer with expectations of perhaps growing to become a billion-dollar seller one day. The only worry seems to be early sales of the drug are headed in the wrong direction. Reporting its fourth-quarter results ,... 
WellPoint’s Argument for 39% Rate Hike: Adverse Selection
WellPoint’s Argument for 39% Rate Hike: Adverse Selection
News that Anthem Blue Cross is raising premiums 39% for some people in California comes at a convenient time for Democrats looking to regain a little health-care-overhaul momentum. So it’s no surprise that HHS Secretary Kathleen Sebelius sent a letter calling on the company to justify the rate increase. After WellPoint, Anthem’s parent... 
Glaxo Cuts 700 U.S. Sales and Marketing Positions
Glaxo Cuts 700 U.S. Sales and Marketing Positions
Some staff have taken buyouts; others are being laid off.  Read More →
Eli Lilly Exec Heads to Harvard Med School
Eli Lilly Exec Heads to Harvard Med School
William Chin , Eli Lilly’s senior VP for discovery and clinical research, is going to take a newly created job at Harvard Medical School. He’ll be the “executive dean for research.” It sounds like at least part of his job will be figuring out how Harvard researchers should interact with industry, as well as working to move... 
Medco’s Snow: More Original Research to Aid Care, Cut Costs
Medco’s Snow: More Original Research to Aid Care, Cut Costs
Pharmacy-benefit manager Medco Health Solutions reported earnings today, and the results didn’t seem to surprise Wall Street too much even though its shares declined. But the company took some time on its call with analysts to highlight its growing push into original research. Medco made a bit of a splash in 2008 when company researchers co-authored... 
Pfizer Scientist Is Plucked to Head AstraZeneca Drug Research
Pfizer Scientist Is Plucked to Head AstraZeneca Drug Research
AstraZeneca has reached across the Atlantic to poach a well-regarded neuroscientist from Pfizer to lead its drug discovery, research and early development efforts, according to people familiar with the hire. Menelas Pangalos was chief scientific officer in charge of neuroscience research at Pfizer, but only for a few months. He had just come from... 
ACOR, Health 2.0 in the US & Europe: Gilles Frydman tells all
By Matthew Holt Gilles Frydman is one of the leading ePatients. He started and runs ACOR (Association of Cancer Online Resources) and has discussed the role of engaged patients with rare diseases at the last few Health 2.0 Conferences. We’ll…  Read More →
  Related Tweets from Twitter
lavangiangel (lavangi angel)  : Heart Oxfordshire : Peru drugs pair await trial - Oxford Mail http://bit.ly/cDWHl5..
Updated : 2010-08-01T09:46:35Z   |  Reply  |  View Tweet
Drugs_Devices (Drugs and Devices OW)  : Some diabetes drugs linked to fractures - UPI.com: A U.S. researcher says post-menopausal women taking some diabet... http://bit.ly/9S4bg0..
Updated : 2010-08-01T09:46:33Z   |  Reply  |  View Tweet
Drugs_Devices (Drugs and Devices OW)  : HCV New Drugs: Veterans were exposed to unclean instruments at VA Hospital: HCV New Drugs: Veterans were exposed t... http://bit.ly/dnV7G9..
Updated : 2010-08-01T09:46:32Z   |  Reply  |  View Tweet
Drugs_Devices (Drugs and Devices OW)  : HCV New Drugs: Veterans were exposed to unclean instruments at VA Hospital: HCV New Drugs: Veterans were exposed t... http://bit.ly/dnV7G9..
Updated : 2010-08-01T09:46:32Z   |  Reply  |  View Tweet
MusicProMag (MusicPro Magazine)  : Twee pop vs guitar hero: If rock *n' roll is only about scoring drugs, groupies and ear-splitting noise, the Scott... http://bit.ly/deP4yU..
Updated : 2010-08-01T09:46:17Z   |  Reply  |  View Tweet
  Related News from Digg
No comments yet.

Spam Protection by WP-SpamFree

TOP